Association of Anticholinergic Drug Burden With Cognitive and Functional Decline Over Time in Dementia With Lewy
Cemile Ozsurekci1, Neslihan Kayahan Satis, Sultan Keskin Demircan
1Division of Geriatrics, Gulhane Faculty of Medicine and Gulhane Training and Research Hospital, University of Health Sciences, 06010, Ankara, Turkey.
Clinical Neuropharmacology
|March 13, 2024
Summary
Anticholinergic burden (ACB) in dementia with Lewy bodies (DLB) patients may worsen functional status and cognitive orientation. This study found ACB negatively impacted daily living activities and orientation over one year.
Area of Science:
- Geriatric Medicine
- Neuroscience
- Pharmacology
Background:
- Dementia with Lewy bodies (DLB) is a progressive neurodegenerative disorder.
- Anticholinergic drugs are commonly prescribed and can cause cognitive and functional side effects.
Purpose of the Study:
- To investigate the association between anticholinergic burden (ACB) and cognitive/functional changes in DLB patients over a 1-year period.
Main Methods:
- A cohort of 112 DLB patients was assessed at baseline, 6, and 12 months.
- Cognition, functional performance, and ACB were evaluated.
- Participants were categorized into ACB ≥1 and ACB=0 groups.
Main Results:
- Patients with ACB ≥1 exhibited lower baseline instrumental activities of daily living (IADL) scores.
- Significant decline in IADL and Barthel index observed in the ACB ≥1 group.
- Deterioration in cognitive orientation noted in the ACB ≥1 group over time.
Conclusions:
- Anticholinergic drug use in DLB patients may increase morbidity.
- Adverse effects on functional status and cognitive orientation are potential risks.
- Further research is needed to mitigate anticholinergic side effects in DLB.
More Related Videos
Related Concept Videos
01:26Alzheimer's Disease: Overview
475
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
475
01:30Dementia
113
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
113
01:22Alzheimer's Disease: Treatment
186
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
186
01:24Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
01:15Parkinson's Disease: Overview
541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
123
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
123